In today’s recent session, 0.88 million shares of the Esperion Therapeutics Inc (NASDAQ:ESPR) have been traded, and its beta is 0.79. Most recently the company’s share price was $1.75, and it changed around -$0.02 or -1.10% from the last close, which brings the market valuation of the company to $344.93M. ESPR at last check was trading at a discount to its 52-week high of $3.94, offering almost -125.14% off that amount. The share price’s 52-week low was $1.57, which indicates that the recent value has risen by an impressive 10.29% since then.
Esperion Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.78. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended ESPR as a Hold, whereas 3 deemed it a Buy, and 1 rated it as Underweight. Esperion Therapeutics Inc is expected to report earnings per share of -0.18 for the current quarter.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Instantly ESPR has been showing red trend so far today with a performance of -1.10% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.8600 on recent trading dayincreased the stock’s daily price by 5.91%. The company’s shares are currently down -20.43% year-to-date, but still up 6.10% over the last five days. On the other hand, Esperion Therapeutics Inc (NASDAQ:ESPR) is -3.28% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 78.12% from its current value. Analyst projections state that ESPR is forecast to be at a low of $8 and a high of $8.
Esperion Therapeutics Inc (ESPR) estimates and forecasts
The year-over-year growth rate is expected to be 4.87%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 54.97M in revenue for the current quarter. 6 analysts expect Esperion Therapeutics Inc to make 61.74M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 137.74M and 73.83M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -60.09%. Forecasts for the next quarter put sales growth at -16.38%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 23.09%.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
BLACKROCK INC., with 8.2617% or 13.98 million shares worth $31.04 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 6.68 shares worth $11.68 million, making up 3.39% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 6.18 shares worth around $10.81 million, which represents about 3.14% of the total shares outstanding.
